Peptides and Gene Therapy: Follistatin, Myostatin Knockout, and CRISPR Delivery

The boundary between peptide biology and gene therapy has never been thinner. As gene editing tools become more precise and gene delivery vectors more sophisticated, researchers have found that some of the most compelling targets for permanent genetic intervention are the same pathways that peptide researchers have been modulating with injectable compounds for years. Follistatin, myostatin, GLP-1, and IGF-1 — all central figures in peptide pharmacology — are now prime targets for gene therapy approaches designed to produce persistent, potentially lifelong biological effects.

Understanding where peptide science and gene therapy intersect helps clarify both the promise and the complexity of each approach. They are often complementary strategies aiming at the same biological targets through fundamentally different mechanisms.

Follistatin Gene Therapy: Permanent Myostatin Suppression

Follistatin is a naturally occurring protein that binds and neutralizes myostatin (GDF-8), the primary inhibitor of muscle growth. In peptide practice, follistatin analogues are used as research peptides to transiently boost muscle anabolism. But follistatin gene therapy aims for something far more durable: permanent upregulation of follistatin expression in muscle tissue.

The approach uses adeno-associated virus (AAV) vectors — engineered viruses stripped of their disease-causing machinery but retaining their ability to enter cells and deliver genetic cargo. When AAV carrying a follistatin gene is injected into muscle tissue, it infects muscle cells and inserts the follistatin gene into the nucleus. The cell then produces follistatin continuously, suppressing local myostatin signaling indefinitely.

Nationwide Children's Hospital's research group, led by Brian Kaspar, published landmark follistatin gene therapy data in patients with Becker muscular dystrophy and limb-girdle muscular dystrophy. Participants showed significant, sustained increases in muscle volume at the injection site over multiple years following a single treatment. The results represent one of the clearest demonstrations of AAV-mediated muscle gene therapy working in humans.

A separate trial used follistatin gene therapy in inclusion body myositis (IBM) — a degenerative muscle disease with no approved treatment — and similarly showed meaningful preservation of muscle function.

The therapeutic implications extend beyond rare muscle diseases. Research groups are exploring whether follistatin gene therapy could be used in sarcopenia (age-related muscle loss) and cachexia (cancer- and disease-related muscle wasting), where systemic muscle preservation could extend survival and quality of life.

Myostatin Knockout: CRISPR Editing at the Source

While follistatin gene therapy suppresses myostatin at the protein level, CRISPR-based approaches aim to permanently silence the myostatin gene itself. This is a more aggressive intervention — rather than adding an inhibitor, you're knocking out the inhibited gene.

CRISPR-Cas9 myostatin knockout has been demonstrated in livestock with dramatic results. Pigs, sheep, and cattle with myostatin disruption develop extraordinary musculature — visibly apparent at birth. In animal models of Duchenne muscular dystrophy, myostatin knockout combined with dystrophin correction produces near-normal muscle function.

The complexity for human application is delivery. CRISPR-Cas9 is itself a protein complex — specifically, it's a guide RNA and a Cas9 protein that together locate and cut a specific DNA sequence. Getting this protein complex into the nucleus of muscle cells throughout the body is a significant technical challenge. Two delivery strategies are most advanced:

AAV-delivered CRISPR: The CRISPR components are encoded in DNA and packaged in AAV vectors. The AAV infects cells, the CRISPR components are expressed, they edit the target gene, and then — ideally — the CRISPR components degrade. This is the approach used in most current muscle-directed CRISPR trials, including dystrophin correction trials.

Peptide-mediated CRISPR delivery: Researchers at MIT, Stanford, and several biotech companies have developed cell-penetrating peptides (CPPs) that can carry the Cas9 protein directly into cells as a protein cargo rather than as genetic material. This approach bypasses the need for a viral vector and potentially reduces off-target editing. CPPs like TAT, penetratin, and designed amphipathic helices have been conjugated to Cas9 to facilitate nuclear delivery. This is one of the most exciting intersection points between peptide science and gene editing.

GLP-1 Gene Therapy for Metabolic Disease

Given the profound success of GLP-1 receptor agonist drugs, it's natural to ask: could a single gene therapy treatment produce lasting GLP-1 effects without repeated injections?

Several research groups have pursued exactly this. AAV-delivered preproglucagon gene (the GLP-1 precursor) targeted to the liver or pancreas produces sustained GLP-1-like peptide secretion in animal models. In diabetic mouse models, single-injection GLP-1 gene therapy has maintained glucose control for the entire lifespan of the animal.

The challenge for human translation is immunogenicity and regulation. The liver is accessible for AAV delivery (intravenous administration), but liver-targeted gene therapies have faced setbacks from immune reactions to AAV capsids. Additionally, continuous GLP-1 production without dose control raises safety questions — you can't simply stop a gene therapy if side effects emerge, whereas you can stop an injection.

Researchers are addressing these concerns with inducible gene expression systems: the gene therapy includes a regulatory switch that can be activated or silenced by an orally administered small molecule. This concept — a "gene therapy with a volume knob" — is central to next-generation metabolic gene therapies.

IGF-1 and Growth Hormone Axis Gene Therapy

IGF-1 (insulin-like growth factor 1) is intimately connected to growth hormone and to muscle and connective tissue anabolism. In peptide practice, sermorelin and CJC-1295/Ipamorelin are used to stimulate growth hormone release, which subsequently drives IGF-1 production. Gene therapy approaches aim to deliver IGF-1 directly to muscle tissue, bypassing the GH-IGF-1 axis entirely.

Tissue-specific IGF-1 gene therapy (mIGF-1, or "mechano growth factor" gene therapy) has shown remarkable results in aged mice — restoring muscle mass and function to levels comparable to young animals with a single injection. Work from H. Lee Sweeney's group at the University of Pennsylvania was foundational here, and it sparked intense interest in IGF-1 gene therapy for aging applications.

Cell-Penetrating Peptides as CRISPR Delivery Vehicles

Cell-penetrating peptides deserve extended attention as delivery tools for gene editing. The fundamental problem with CRISPR as a medicine is getting a large protein (Cas9 is approximately 158 kilodaltons) into specific cell types in a living human body. Viral vectors work but bring immunogenicity concerns. Lipid nanoparticles work for the liver but have limited tissue tropism.

CPPs offer a flexible, synthetic alternative. These short sequences — often 8–30 amino acids — exploit charge-based, hydrophobic, or amphipathic properties to cross cell membranes that would otherwise exclude large molecules. When covalently linked or electrostatically associated with Cas9, guide RNA, or base editors, CPPs can deliver functional gene editing machinery into cells.

Several important CPP-CRISPR applications are under active development:

• Tumor-targeted CRISPR: CPPs derived from tumor-homing sequences direct Cas9 to cancer cells for targeted gene disruption
• Muscle-specific CPPs: Peptides with affinity for dystrophin-deficient muscle cells are in development for DMD gene editing
• CNS-penetrating CPPs: Short peptides that cross the blood-brain barrier are being evaluated for neurological CRISPR applications

The efficiency of CPP-mediated delivery currently lags behind viral vectors, but the safety profile and manufacturing simplicity of all-synthetic systems makes them attractive for certain applications.

Epigenetic Editing with Peptide Tools

Beyond classical gene knockout and transgene delivery, a newer area of gene therapy uses epigenetic editing — changing gene expression without altering the underlying DNA sequence. Peptide-based epigenetic tools include:

BRD4-targeting peptides: BRD4 is a bromodomain reader protein that drives expression of many oncogenes. Peptides that block BRD4's chromatin-reading function suppress these oncogenes without genetic editing — a pharmacological approach that mimics gene silencing.

Peptide-KRAB fusions: Researchers have fused CPPs to KRAB repressor domains (transcriptional silencers) to create transient gene silencing tools that work at the protein level rather than at the DNA level.

Regulatory and Ethical Landscape

Gene therapy with peptide-related targets occupies a heavily regulated space. Somatic gene therapy — modifying non-reproductive cells in a living patient — is the focus of current clinical development and is generally considered ethically acceptable when conducted in the context of serious disease.

The same cannot be said for germline editing or enhancement applications. CRISPR myostatin knockout in healthy humans, for example, would face enormous regulatory barriers and ethical scrutiny, regardless of how effective it might be. The He Jiankui case — in which a researcher illegally edited human embryos — has made the entire field acutely aware of the regulatory and societal dimensions of human genome editing.

For now, all legitimate human gene therapy applications target serious diseases with unmet medical need, which is precisely where the peptide-gene therapy intersection is most productive.

Frequently Asked Questions

Q: Is follistatin gene therapy available for humans? Follistatin gene therapy is in clinical trials for specific muscle diseases (muscular dystrophies, inclusion body myositis). It is not available as a general muscle-building therapy, nor is it approved outside of clinical trial settings. Participating requires enrollment in an IRB-approved trial.

Q: How is CRISPR different from traditional gene therapy? Traditional gene therapy typically adds a functional copy of a gene (gene addition). CRISPR is a gene editing tool that can precisely cut DNA at specific sequences, enabling gene disruption, correction, or the insertion of new sequences. CRISPR offers more precise control but introduces concerns about off-target edits.

Q: Can peptides be used to deliver CRISPR components? Yes. Cell-penetrating peptides can carry Cas9 protein and guide RNA into cells, serving as a non-viral delivery vehicle for CRISPR gene editing. This approach is active in research and early preclinical development, though viral vectors remain more efficient for most in vivo applications.

Q: What is the difference between somatic and germline gene therapy? Somatic gene therapy modifies non-reproductive cells in a living person — the changes only affect that individual and are not heritable. Germline gene therapy modifies reproductive cells (eggs, sperm, or embryos), meaning the changes would be passed to future generations. Somatic gene therapy for disease treatment is legally conducted in clinical trials; germline editing in humans is broadly prohibited in most countries.

Q: Will gene therapy eventually replace peptide injections for muscle or metabolic conditions? For some conditions, gene therapy may offer "one-and-done" solutions superior to chronic peptide administration. However, gene therapy currently has higher upfront cost, less reversibility, and longer regulatory pathways. Peptide injections offer dose flexibility and reversibility that gene therapy cannot. Both approaches will likely coexist, with gene therapy gaining ground for rare diseases and severe conditions where chronic injectable therapy is burdensome.